Clinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor.
Infante J, Powderly J, Burris H, Kittaneh M, Grice J, Smothers J, Brett S, Fleming M, May R, Marshall S, Devenport M, Pillemer S, Pardoll D, Chen L, Langermann S, LoRusso P. Clinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor. Journal Of Clinical Oncology 2013, 31: 3044-3044. DOI: 10.1200/jco.2013.31.15_suppl.3044.Peer-Reviewed Original ResearchPD-1B7-H1T cellsFunctional T cell responsesT cell effector functionPK/PD relationshipInflammatory adverse eventsPD-1 axisAdvanced solid tumorsPre-treatment biopsiesTumor immune evasionPhase I trialT cell poolT cell responsesInitial disease progressionPD-1 receptorCell effector functionsFunctional T cellsMultiple tumor typesBaseline tumorPD-1highStable diseaseB7-DCLymphocyte subsetsAdverse events